https://pnd-1186inhibitor.com/....superfrogs-from-the-
Regardless of the specific treatment, sarcopenia served as a predictor for radiographic progression (aHR = 2.39, 95% CI = 1.06-5.36, p = 0.0035) and overall mortality (aHR = 2.44, 95% CI = 1.17-5.08, p = 0.0018). In male patients with metastatic castration-resistant prostate cancer (mCRPC), baseline sarcopenia is a predictor of adverse outcomes, including radiographic progression, higher mortality rates, and potentia
Like
Comment
Share
